Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

profits from sales of fexofenadine hydrochloride tablets from Teva, which began in September 2005, and lower income from the royalty earned under its April 2005 agreements with Kos Pharmaceuticals relating to the Niaspan(R) and Advicor(R) cholesterol lowering agents. These declines were partially offset by an increase in royalties and other fees received under the Company's agreements with Shire plc.

Other Revenue

Other revenue primarily includes revenue from non-core operations acquired in connection with the PLIVA acquisition, including the diagnostic, disinfectants, dialysis and infusions business. Other revenue totaled $45 million for calendar 2007 and $12 million for the fourth quarter of 2007.

Margins

Generic: Margins in the generic segment were 47% for both the quarter and year ended December 31, 2007.

Proprietary: Margins in the proprietary segment for the quarter and year ended December 31, 2007 were 55% and 68%, respectively. Proprietary margins for the fourth quarter ended December 31, 2007 were negatively impacted by a $13.7 million, or $0.08 per share, charge related to a product royalty contingency agreement for the Company's Cenestin(R) product.

Update on R&D Activities

Research and development investment for the quarter and year ended December 31, 2007 totaled $62 million and $248 million, respectively.

Generic Products

During 2007, the Company filed 30 Abbreviated New Drug Applications (ANDAs), resulting in approximately 70 ANDAs, including tentatively approved applications pending at the U.S. Food and Drug Administration (FDA) at the end of the year. These ANDAs target branded pharmaceutical products with an estimated $29 billion in annual sales. The Company also filed 224 product registrations, representing 65 molecules with regulatory bodies in Europe and in the ROW during 2007, resulting in 287 product registrations, representing 90 molecules pending with regulatory bodies in Europe
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Becht Engineering Co., Inc., ... has acquired The CECON Group, Inc., located in ... not announced. , Becht Engineering (http://www.becht.com ) ... including oil and gas production, refining, petrochemical, chemical, ... power sectors. The company has twelve offices in ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. , ... is to match the right drug to the ... design the appropriate treatment for a patient according ...
(Date:3/3/2015)... 2015  Johnson & Johnson Innovation LLC today announced ... (JLABS @SSF), a 30,000-square foot incubator located ... Francisco, Calif. The Johnson & Johnson Innovation, ... from across the healthcare spectrum including biotech, pharmaceutical, medical ... first resident startups have been selected, including the winners ...
(Date:3/3/2015)... ROCKVILLE, Md. , March 3, 2015  Synthetic Biologics, ... serious infections and diseases, with a focus on protecting the ... Officer, is scheduled to present at the 27th Annual ROTH ... Laguna Niguel in Dana ... on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time). ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... Valeant,Pharmaceuticals International (NYSE: VRX ) ... to acquire Dow Pharmaceutical Sciences, Inc., a privately,held ... topical,products on a proprietary basis, as well as ... enhances Valeant,s,dermatology franchise in the United States through ...
... Resource enable researchers to quickly and effectively use this invaluable resource. ... ... OpenHelix today announced the availability of a new tutorial ... a public resource for the analysis of prokaryotes, including the complete ...
... Dec. 9 ev3 Inc. (Nasdaq: ... that it has received,510(k) clearance from the U.S. ... 0.035" and NanoCross 0.014" peripheral angioplasty balloon,catheters. ... EverCross and,NanoCross peripheral balloon catheters globally in January ...
Cached Biology Technology:Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 2Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 3Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 4Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 5New Online Tutorial for the Comprehensive Microbial Resource (CMR) 2ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons 2ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons 3
(Date:1/22/2015)... the leading source of biometrics industry news, interviews and thought ... "When we launched FindBiometrics 12 years ago the industry ... and CEO of FindBiometrics. "Now it,s maturing very quickly. More ... on a very broad scale.  We are known for providing ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... and POINT ROBERTS, Washington , January 20, ... leading sectors including technology and tech stocks, releases video from ... master pickpocket and security consultant Apollo Robbins . ... talks about the Wocket™ biometric smart wallet, a product of ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... Cell-based therapies have been shown to enhance ... produced only "modest results." In an effort to ... team from Germany has taken epithelial cells from ... them into mesenchymal cells. After transplanting the transitioned ...
... better at repelling attacks by mountain pine beetles, which have ... by the University of Colorado Boulder. The findings, published ... land managers make decisions about which trees to cull and ... against pine beetle infestation. The current mountain pine beetle ...
... the important transducers of noxious stimuli in the primary ... and hyperalgesia. However, there is no direct evidence that ... neuropeptide release from primary afferent neurons. A recent study ... Medicine in Japan demonstrated for the first time that ...
Cached Biology News:Transitioning epithelial cells to mesenchymal cells enhances cardiac protectivity 2Slippery bark protects trees from pine beetle attack, according to CU-Boulder study 2